Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Zentalis Pharmaceuticals, Inc. ZNTL
$26.77
+$0.67 (2.49%)
На 18:02, 12 мая 2023
+75.57%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1361277835.00000000
-
week52high
32.34
-
week52low
15.55
-
Revenue
0
-
P/E TTM
-15
-
Beta
1.83037000
-
EPS
-4.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 11:00
Описание компании
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 11 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 10 авг 2022 г. |
| Cowen & Co. | Outperform | 12 июл 2022 г. | |
| SVB Leerink | Outperform | Outperform | 12 апр 2022 г. |
| Wedbush | Outperform | Outperform | 14 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 11 ноя 2022 г. |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 ноя 2022 г. |
| Oppenheimer | Outperform | Outperform | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bunker Kevin D. | A | 132646 | 132646 | 01 февр 2023 г. |
| Bunker Kevin D. | A | 875464 | 91354 | 01 февр 2023 г. |
| Brownstein Carrie | A | 23687 | 23687 | 01 февр 2023 г. |
| Brownstein Carrie | A | 116313 | 16313 | 01 февр 2023 г. |
| Paul Andrea | A | 59217 | 59217 | 01 февр 2023 г. |
| Paul Andrea | A | 40783 | 40783 | 01 февр 2023 г. |
| Epperly Melissa B, | A | 148043 | 148043 | 01 февр 2023 г. |
| Epperly Melissa B, | A | 399899 | 101957 | 01 февр 2023 г. |
| Blackwell Kimberly | A | 355200 | 355200 | 01 февр 2023 г. |
| Blackwell Kimberly | A | 249800 | 244800 | 01 февр 2023 г. |
Новостная лента
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
GlobeNewsWire
01 февр 2023 г. в 07:01
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences.
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
GlobeNewsWire
31 авг 2022 г. в 07:00
NEW YORK and SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences.
Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
26 авг 2022 г. в 13:33
Zentalis Pharmaceuticals, Inc. (ZNTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Zentalis Pharmaceuticals (ZNTL) Might Surprise This Earnings Season
Zacks Investment Research
10 авг 2022 г. в 09:47
Zentalis Pharmaceuticals (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pfizer Injects $25M Via Equity In Zentalis Pharma
Benzinga
27 апр 2022 г. в 10:19
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) will sell 953,834 common shares at $26.21 per share to Pfizer Inc (NYSE: PFE) for $25 million. The offering is expected to close by April 29.